Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF‐β‐dependent manner

Daniel R. Tonkin, Kathryn Haskins

European Journal of Immunology · 2009 · 49 citations · 42 references

DOIFull text

Open access

Concepts

TL;DR

Regulatory T cells can suppress autoimmune diseases such as type 1 diabetes, yet their in vivo activity within the pancreas, the site of islet destruction, remains poorly understood. The study aimed to generate islet‑specific TGF‑β–induced regulatory T cells from BDC‑6.9 TCR transgenic mice. These TGF‑β–induced Tregs were transferred into scid mice that received diabetic NOD spleen cells or activated BDC‑2.5 Th1 effector T cells to assess their suppressive function. The transferred Tregs suppressed spontaneous and transferred diabetes, infiltrated the pancreas, reduced effector Th1 T cells and.

Abstract

Abstract Treg can suppress autoimmune diseases such as type 1 diabetes, but their in vivo activity during suppression remains poorly characterized. In type 1 diabetes, Treg activity has been demonstrated in the pancreatic lymph node, but little has been studied in the pancreas, the site of autoimmune islet destruction. In this study we induced islet‐specific Treg from the BDC‐6.9 TCR transgenic mouse by activation of T cells in the presence of TGF‐β. These Treg can suppress spontaneous diabetes as well as transfer of diabetes into NOD. scid mice by diabetic NOD spleen cells or activated BDC‐2.5 TCR transgenic Th1 effector T cells. In the latter transfer model, we observed infiltration of the pancreas by both effector T cells and Treg, suggesting that Treg are active in the inflammatory site and are not just restricted to the draining lymph node. Within the pancreas, we demonstrate that Treg transfer causes a reduction in the number of effector Th1 T cells and macrophages, and also inhibits effector T‐cell cytokine and chemokine production. Although we found no role for TGF‐β in vitro , transfection of effector T cells with a dominant‐negative TGF‐β receptor demonstrated that in vivo suppression of diabetes by TGF‐β‐induced Treg is TGF‐β‐dependent.

References

42